Financials data is unavailable for this security.
View more
Year on year Bioventus Inc had relatively flat revenues (512.12m to 512.35m), though the company grew net income from a loss of 158.70m to a smaller loss of 156.23m. A reduction in the selling, general and administrative costs as a percentage of sales from 64.86% to 59.31% was a component in the net income growth despite flat revenues.
| Gross margin | 67.00% |
|---|---|
| Net profit margin | -9.22% |
| Operating margin | -3.39% |
| Return on assets | -6.47% |
|---|---|
| Return on equity | -24.20% |
| Return on investment | -9.13% |
More ▼
Cash flow in USDView more
In 2023, Bioventus Inc increased its cash reserves by 16.10%, or 5.13m. Cash Flow from Investing totalled 15.81m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 15.34m in cash from operations while cash used for financing totalled 26.65m.
| Cash flow per share | -0.0243 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.83 |
|---|---|
| Tangible book value per share | -3.37 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.41 |
|---|---|
| Quick ratio | 0.9866 |
| Total debt/total equity | 2.58 |
|---|---|
| Total debt/total capital | 0.6725 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 8.78%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 63.07 |
